Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically
meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

9065 Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid …

Background Selpercatinib, a first-in-class highly selective and potent CNS-active RET
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ NSCLC. In …

Introduction: Oncogenic alterations in RET occur in 1–2% of non-small-cell lung cancers
(NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET …

Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in
non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have …

Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET
kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in …

3584 Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule
RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in …